Sign In
Buy XOMA
$32.03
-0.610 (-1.87%)
At Close: Nov 17, 2025
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
09:46am, Wednesday, 12'th Nov 2025
XOMA Royalty (XOMA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.39 per share a year ago.
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
07:30am, Wednesday, 12'th Nov 2025
Business development : Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics.
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
04:09pm, Monday, 10'th Nov 2025
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed
Financial Survey: Cognition Therapeutics (NASDAQ:CGTX) versus XOMA Royalty (NASDAQ:XOMA)
02:49am, Sunday, 26'th Oct 2025
Cognition Therapeutics (NASDAQ: CGTX - Get Free Report) and XOMA Royalty (NASDAQ: XOMA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO
Compass Therapeutics (NASDAQ:CMPX) & XOMA Royalty (NASDAQ:XOMA) Head-To-Head Survey
01:48am, Wednesday, 22'nd Oct 2025
Compass Therapeutics (NASDAQ: CMPX - Get Free Report) and XOMA Royalty (NASDAQ: XOMA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
11:45am, Friday, 17'th Oct 2025
- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Nether
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
08:00am, Friday, 03'rd Oct 2025
XOMA Royalty Corporation preferred stocks offer diversification beyond mREITs and banks, but both XOMAO and XOMAP are now rated Sell. Recent high-cost financing and low tangible common equity raise ri
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
04:43pm, Thursday, 02'nd Oct 2025
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V.
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
06:00am, Wednesday, 24'th Sep 2025
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October
XOMA Royalty Declares Quarterly Preferred Stock Dividends
07:30am, Monday, 22'nd Sep 2025
EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Roy
Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?
10:55am, Friday, 19'th Sep 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 85.3% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the p
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
09:00am, Wednesday, 17'th Sep 2025
EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
10:56am, Wednesday, 03'rd Sep 2025
The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
07:30am, Wednesday, 03'rd Sep 2025
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Inve
